Aaron Ring, M.D., Ph.D.

Aaron is the Founder of Simcha Therapeutics and a widely-recognized leader in cytokine engineering for which he was named to Endpoints “20 under 40 in Biopharma in 2022” and Nature Biotechnology’s “Top 20 Translational Researchers of 2020.” He led the development of decoy-resistant IL-18 in his laboratory at the Yale School of Medicine where he is an Associate Professor of Immunobiology.

Jeremy Barton, M.D.

Jeremy has over 30 years of experience in all phases of oncology drug development in the pharmaceutical industry in Switzerland, UK and currently in the US. He is now working as a self-employed consultant, advising biotech companies on strategic oncology drug development.

Most recent industry responsibilities in the US have included Chief Medical Officer roles at Biogen Idec, eFFECTOR Therapeutics and Mirati Therapeutics. He was also head of early Oncology Development at Pfizer (San Diego) for 5 years overseeing the transition of all Oncology compounds from research through IND to proof-of-concept studies.

After obtaining a master’s degree in Physiology from Oxford University and his M.D. degree at University College Hospital Medical School in London, he trained in Internal Medicine and Clinical Oncology in the United Kingdom and practiced for 11 years in the National Health Service.

Jeremy is Board Certified in Internal Medicine and Clinical Oncology, a Member of the Royal College of Physicians, a Fellow of the Royal College of Radiologists (Clinical Oncology) and a Member of Faculty of Pharmaceutical Medicine.

Tom Boone, M.S.

Tom has more than 40 years of accomplishments in the discovery and development of protein therapeutics. Tom worked at Amgen for 28 years and served in positions of increasing responsibility in growing Amgen Protein Sciences to an organization of over 300 researchers across five different sites. His career at Amgen began in 1981 as a bench scientist with the isolation and cDNA cloning of novel cytokines and growth factors including G-CSF. He was also responsible for expressing, purifying, and formulating many of Amgen’s recombinant proteins. Tom developed proprietary processes used to produce recombinant G-CSF and other therapeutic candidates for clinical applications. Tom was the first Vice President of Amgen Protein Science. Tom was the lead scientist in the development of Nplate®, a treatment of thrombocytopenia. His critical role in the discovery and process development of G-CSF (Neupogen) is widely recognized. Tom has Masters degrees in Microbiology from UCLA and Soil Science from UC Davis. Tom has recently helped start several companies and has helped them license in clinical stage molecules. He is currently a consultant or scientific advisor for more than 30 companies, providing both strategic and technical guidance.

Beatrice McQueen, Ph.D.

Beatrice has 20+ years of industry experience in research and development, operations, finance and business development. Beatrice was appointed a Simcha executive since its inception in 2018 accountable for all aspects of the company – G&A, Corporate Strategy and R&D, including manufacturing, preclinical & clinical development, regulatory and quality. Prior to Simcha, she served on the commercial team at PPD. Before PPD, Beatrice established and led Beatrice Perotti Inc in 2006, a consulting firm, full time for 12 years until 2017, providing consulting services to start ups and established biotech companies. Beatrice started consulting after 12 years of product development and finance experience in leadership positions in PKDM, product strategy/early development, strategic business operations and finance at Pfizer and Amgen. 

Beatrice graduated with a Ph.D. in Pharmaceutical Chemistry – Pharmacokinetics & Drug Metabolism from the University of California, San Francisco, and an E.M.B.A. from UCLA Anderson School of Management. Beatrice also had a Project Management Certificate from CalTech and was an Amgen certified Six Sigma Black Belt.

Sanuj Ravindran, M.D.

Sanuj has spent more than 20 years in strategic and operational roles across the life science industry, both as an investor and company builder. Most recently, he served as CEO-in-residence at BridgeBio (BBIO) where he was chief executive officer of PellePharm, and executive chair of Phoenix Tissue Repair. In these roles, Sanuj led both companies’ growth, directed strategy, secured significant partnerships, and advanced pipeline programs in oncology and rare skin diseases through mid- and late-stage clinical trials. Before this, he served as chief business officer at aTyr Pharma (LIFE), a clinical-stage protein therapeutics company focused on tRNA synthetases. Prior to that, Sanuj was senior vice president of corporate development at The Medicines Company (MDCO), where he led multiple transactions totaling more than $2 billion in potential value. Sanuj began his biotech career as a venture capitalist for 10 years with Burrill & Company, Radius Ventures, and Asian Healthcare Fund. 

Sanuj was previously a practicing physician, board-certified in Internal Medicine, having completed his residency training at Thomas Jefferson University Hospital. He received his bachelor’s degree from Northwestern University, his doctorate in medicine from Jefferson Medical College, and his master’s of business administration from the Kellogg School of Management.